Cargando…
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods:...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268494/ https://www.ncbi.nlm.nih.gov/pubmed/34209880 http://dx.doi.org/10.3390/jcm10132914 |
_version_ | 1783720370883264512 |
---|---|
author | Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro-de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobaton, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero-Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
author_facet | Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro-de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobaton, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero-Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
author_sort | Albshesh, Ahmad |
collection | PubMed |
description | Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. |
format | Online Article Text |
id | pubmed-8268494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82684942021-07-10 Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro-de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobaton, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero-Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri J Clin Med Article Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. MDPI 2021-06-29 /pmc/articles/PMC8268494/ /pubmed/34209880 http://dx.doi.org/10.3390/jcm10132914 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro-de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobaton, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero-Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_full | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_fullStr | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_full_unstemmed | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_short | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_sort | effectiveness of third-class biologic treatment in crohn’s disease: a multi-center retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268494/ https://www.ncbi.nlm.nih.gov/pubmed/34209880 http://dx.doi.org/10.3390/jcm10132914 |
work_keys_str_mv | AT albsheshahmad effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT taylorjoshua effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT savarinoedoardov effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT truyensmarie effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT armuzzialessandro effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT ribaldonedavideg effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT shitritariellabargil effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT fibelmanmorine effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT molanderpauliina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT liefferinckxclaire effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT nanceystephane effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT koranimohamed effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT rutkamariann effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT barreirodeacostamanuel effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT domislovicviktor effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT surisgerard effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT erikssoncarl effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT alvescatarina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT mpitouliafroditi effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT dijiangcaroline effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT tepeskatja effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT colettamarina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT foteinogiannopouloukalliopi effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT gisbertjavierp effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT amirbarakhadar effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT attauabimohamed effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT seidelinjakob effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT afifwaqqas effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT marinellicarla effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT lobatontriana effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT pugliesedaniela effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT maharshaknitsan effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT cremeranneline effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT limdijimmyk effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT molnartamas effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT oteroalvarinborja effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT krznariczeljko effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT magrofernando effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT karmiriskonstantinos effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT rainetim effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT drobnedavid effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT koutroubakisioannis effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT chaparromaria effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT yanaihenit effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT burischjohan effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy AT kopylovuri effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy |